A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants with Dravet Syndrome (ARGUS Trial)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518628-57-00

Acronym

EPX-100-001

Enrollment

Registered

2024-12-10

Start date

2023-08-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dravet syndrome

Brief summary

The percent change in CMS-28 in the Maintenance Period relative to baseline.

Interventions

DRUGApart from the active substance

DRUGthe placebo is identical to the investigational medicinal product.

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The percent change in CMS-28 in the Maintenance Period relative to baseline.	—

Countries

Hungary, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026